Bihi Pharmaceuticals is a Dubai-based pharmaceutical company focused on licensing and distribution partnerships for high-quality ophthalmic and essential medicinal products across MENA and emerging markets.
Bihi Pharmaceuticals collaborates with selected distributors through a licensing-based partnership model focused on long-term, country-exclusive agreements.
Our partnership model includes:
We are currently engaging with distributors in Saudi Arabia, GCC countries, and selected African markets.
Bihi Pharmaceuticals follows a disciplined and focused approach to pharmaceutical development and commercialization. Rather than pursuing broad portfolios or rapid geographic expansion, the company prioritizes a limited number of essential generic medicines aligned with national treatment guidelines and local healthcare needs.
Market entry strategies are designed to ensure regulatory clarity, operational control, and long-term sustainability. Engagements with manufacturing partners, distributors, and consultants are conducted through defined governance processes, including NDA-based discussions and structured commercialization frameworks.
Manufacturing activities are conducted through carefully selected WHO-GMP compliant partners. Quality oversight, documentation standards, and batch release processes are aligned with international regulatory expectations.
This approach enables consistent product quality while maintaining operational efficiency and scalability.
Initial commercial activities are directed toward selected markets across MENA and Africa, with an initial focus on ophthalmic and essential medicines.
Market entry strategies are designed in alignment with national treatment guidelines and local regulatory frameworks.
Structured regulatory strategies and high-quality dossiers aligned with local authority requirements.
WHO-GMP compliant production through experienced manufacturing partners.
Controlled market entry through selected local distribution partners.